Cullinan Therapeutics releases Phase 1b/2a Genrix data for velinotamig in lupus at ACR26

Cullinan Therapeutics released clinical data from its ongoing Phase 1b/2a Genrix study of velinotamig in systemic lupus erythematosus. Results are being presented at ACR26 as the company advances its broader autoimmune and oncology pipeline.

Detected & updated continuously · Source: Nebula